Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,621 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,498 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06039202 | CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer | suspended | Phase 2 | 100 | Holy Stone Healthcare Co., LtdINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) | suspended | Phase 2 | 90 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | suspended | Phase 1 / Phase 2 | 53 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05062889 | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients(ERASE-CRC) | suspended | Phase 2 | 477 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05358704 | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer | suspended | Phase 2 | 38 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05591534 | Endorectal Brachytherapy for Rectal Cancer(ICUREC) | suspended | Phase 2 | 31 | University Hospital, BordeauxOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05375708 | Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites(SIRIUS) | suspended | Phase 2 | 93 | UMC UtrechtOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04840186 | EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden(EXCALIBUR3) | suspended | Phase 2 | 62 | Oslo University HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04558684 | Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer | suspended | Phase 1 / Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01872104 | Safety and Efficiency of Photodynamic Therapy for Rectal Cancer(PDT-R-01) | suspended | Phase 2 / Phase 3 | 100 | li xiongOTHER | 1 | Jun 7, 2013 | clinicaltrials |
| NCT00609310 | Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence | suspended | Phase 2 | 382 | Technische Universität DresdenOTHER | 1 | Feb 3, 2012 | clinicaltrials |
| NCT00443573 | Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer | suspended | Phase 1 / Phase 2 | 100 | ARCA Biopharma, Inc.INDUSTRY | 1 | May 7, 2008 | clinicaltrials |
Data updated 11 days agoSource updated Sep 18, 2026source: clinicaltrials